A detailed history of Mount Yale Investment Advisors, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Mount Yale Investment Advisors, LLC holds 4,661 shares of HALO stock, worth $303,850. This represents 0.02% of its overall portfolio holdings.

Number of Shares
4,661
Previous 12,936 63.97%
Holding current value
$303,850
Previous $825,000 70.67%
% of portfolio
0.02%
Previous 0.07%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 12, 2025

SELL
$47.91 - $70.14 $396,455 - $580,408
-8,275 Reduced 63.97%
4,661 $242,000
Q1 2025

Apr 16, 2025

BUY
$47.74 - $65.16 $346,735 - $473,257
7,263 Added 128.03%
12,936 $825,000
Q4 2024

Jan 22, 2025

SELL
$42.57 - $61.09 $396,113 - $568,442
-9,305 Reduced 62.12%
5,673 $271,000
Q3 2024

Oct 23, 2024

BUY
$51.3 - $64.42 $768,371 - $964,882
14,978 New
14,978 $856,000
Q4 2022

Feb 13, 2023

BUY
$40.06 - $59.44 $147,540 - $218,917
3,683 New
3,683 $209,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $9.08B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Mount Yale Investment Advisors, LLC Portfolio

Follow Mount Yale Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mount Yale Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mount Yale Investment Advisors, LLC with notifications on news.